Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Driven by 1 paper. Top paper: “A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children’s Oncology Group”.
Alexander J. Chou, Allen Buxton, Joel M. Reid, Michael S. Isakoff, Lisa M. Kopp +12 more